EGFR and non-small cell lung carcinoma: Nevertheless, 20–30% of NSCLC patients with amplified wild-type EGFR (wtEGFR) still demonstrated significant survival benefits from gefitinib and erlotinib treatment even though they showed lower response rate compared with patients with EGFR mutations [7], [8], [9].